Learn how tirzepatide, a dual GLP‑1/GIP agonist, improves blood sugar control and drives double‑digit weight loss. Discover its mechanism, clinical benefits for type 2 diabetes, and its emerging role in obesity treatment.
Discover why retatrutide is being called the “next‑gen tirzepatide.” Learn how this triple GIP, GLP‑1, and glucagon receptor agonist drives bariatric‑level weight loss, boosts energy expenditure, and improves cardiometabolic health in obesity.